Longboard Pharmaceuticals (NASDAQ:LBPH) Earns Buy Rating from Analysts at Citigroup

Citigroup began coverage on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research report sent to investors on Friday, Marketbeat reports. The firm issued a buy rating and a $40.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald raised their price objective […]

Related Keywords

United States ,Montreal ,Quebec ,Canada ,American , ,Longboard Pharmaceuticals Stock ,American International Group Inc ,Longboard Pharmaceuticals Inc ,Citigroup ,Arena Pharmaceuticals Inc ,Institutional Trading Of Longboard Pharmaceuticals ,News Ratings For Longboard Pharmaceuticals Daily ,Cantor Fitzgerald ,Bourgeon Capital Management ,Analyst Recommendations For Longboard Pharmaceuticals ,York Mellon Corp ,Securities Exchange Commission ,Longboard Pharmaceuticals ,Longboard Pharmaceuticals Company Profile ,Td Asset Management Inc ,Free Report ,Exchange Commission ,Management Inc ,Montreal Can ,International Group ,Capital Management ,New York Mellon Corp ,Get Free Report ,Longboard Pharmaceuticals Daily ,Nasdaq Lbph ,Lbph ,Medical ,Initiated Coverage ,Citigroup Inc ,